GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Cash-to-Debt

Tourmaline Bio (Tourmaline Bio) Cash-to-Debt : 489.04 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Tourmaline Bio Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Tourmaline Bio's cash to debt ratio for the quarter that ended in Dec. 2023 was 489.04.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Tourmaline Bio could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Tourmaline Bio's Cash-to-Debt or its related term are showing as below:

TRML' s Cash-to-Debt Range Over the Past 10 Years
Min: 1   Med: 16.39   Max: 489.04
Current: 489.04

During the past 3 years, Tourmaline Bio's highest Cash to Debt Ratio was 489.04. The lowest was 1.00. And the median was 16.39.

TRML's Cash-to-Debt is ranked better than
86.11% of 1541 companies
in the Biotechnology industry
Industry Median: 6.49 vs TRML: 489.04

Tourmaline Bio Cash-to-Debt Historical Data

The historical data trend for Tourmaline Bio's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Tourmaline Bio Cash-to-Debt Chart

Tourmaline Bio Annual Data
Trend Dec21 Dec22 Dec23
Cash-to-Debt
1.00 16.39 489.04

Tourmaline Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Cash-to-Debt Get a 7-Day Free Trial N/A 16.39 178.10 231.90 489.04

Competitive Comparison of Tourmaline Bio's Cash-to-Debt

For the Biotechnology subindustry, Tourmaline Bio's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tourmaline Bio's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tourmaline Bio's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Tourmaline Bio's Cash-to-Debt falls into.


Tourmaline Bio Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Tourmaline Bio's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=202.951 / (0.221 + 0.194)
=489.04

Tourmaline Bio's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio= Cash, Cash Equivalents, Marketable Securities / Total Debt
= Cash, Cash Equivalents, Marketable Securities / (Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation)
=202.951 / (0.221 + 0.194)
=489.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tourmaline Bio  (NAS:TRML) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Tourmaline Bio Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Tourmaline Bio's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Tourmaline Bio (Tourmaline Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tourmaline Bio Inc (NAS:TRML) » Definitions » Cash-to-Debt
Comparable Companies
CYTK NUVL KRYS CRSP INSM FOLD BPMC IMGN AXSM ACAD OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
27 West 24th Street, Suite 702, New York, NY, USA, 10010
Website
https://www.tourmalinebio.com
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.